Skip to main content

Table 2 Treatment efficacy in patients (N = 17)

From: A phase II study of Endostatin in combination with paclitaxel, carboplatin, and radiotherapy in patients with unresectable locally advanced non-small cell lung cancer

Treatment efficacy

No. of patients

%

Response

 Overall response rate

13

76.4

 Disease control rate

15

88.2

 Complete response

1

5.9

 Partial response

12

70.6

 Stable disease

2

11.7

 Progressive disease

2

11.7

Survival

 Median PFS (months)

10.0 (95 % CI: 7.6–12.3 months)

 Median OS (months)

14.0 (95 % CI: 10.7–17.2 months)